Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

New Microbes and New Infections

H.V. Hofmann¹  Z.M. Holliday²  A.P. Earhart³  A.G. Schrum⁴ 

[1] Corresponding author: A.P. Earhart, M627 Medical Sciences Building, One Hospital Drive, Columbia, MO, 65212, USA.;Therapeutics Program, University of Missouri Graduate School, Columbia, MO, USA;;Molecular Pathogenesis &Pulmonary Disease, Critical Care Medicine, School of Medicine, University of Missouri, Columbia, MO, USA;

关键词: acute respiratory distress syndrome;    COVID-19;    DNAse 1;    dornase alfa;    Neutrophil extracellular trap;   

DOI  :  

来源: DOAJ

【 摘 要 】

We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be considered for clinical trials in treatment of severe COVID-19.

【 授权许可】

Unknown